Advanced cardiac life support antiarrhythmic drugs.
As exemplified in this discussion of ACLS antiarrhythmic drugs, the evidence-based evaluation process has created a high standard for the acceptance and ranking of therapies for cardiac arrest. This process also has identified critical areas needing further investigation, fostered a healthy sense of discomfort with the adequacy of our present interventions for cardiac arrest, and hopefully will continue to spur the science while sifting the dogma out of CPR.
Kudenchuk
Peter J
PJ
Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
D000638:Amiodarone / Q000008:administration & dosage; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001949:Bretylium Compounds / Q000008:administration & dosage; D016887:Cardiopulmonary Resuscitation / Q000379:methods; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006323:Heart Arrest / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage; D008020:Life Support Care / Q000379:methods*; D008274:Magnesium / Q000008:administration & dosage; D008297:Male; D011342:Procainamide; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D008012:Lidocaine; D008274:Magnesium; D011342:Procainamide; D000638:Amiodarone; C045166:bretylium